Publications

Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al. VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. American Journal of Human Genetics. 2020; 107:1149-1156.

Risinger, M; Kalfa, TA. Red cell membrane disorders: structure meets function. Blood. 2020; 136:1250-1261.

Konstantinidis, DG; Pushkaran, S; Johnson, JF; Cancelas, JA; Manganaris, S; Harris, CE; Williams, DA; Zheng, Y; Kalfa, TA. Signaling and cytoskeletal requirements in erythroblast enucleation. Blood. 2012; 119:6118-6127.

Romano, LM; Seu, KG; Papoin, J; Muench, DE; Konstantinidis, D; Olsson, A; Schlum, K; Chetal, K; Chasis, JA; Mohandas, N; et al. Erythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis. Blood. 2022.

Gibson, SJ; Kalfa, TA; DeStefano, CB. Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis. American Journal of Hematology. 2022.

Tu, Z; Fan, C; Davis, AK; Hu, M; Wang, C; Dandamudi, A; Seu, KG; Kalfa, TA; Lu, QR; Zheng, Y. Autism-associated chromatin remodeler CHD8 regulates erythroblast cytokinesis and fine-tunes the balance of Rho GTPase signaling. Cell Reports. 2022; 40.

Noomuna, P; Hausman, JM; Sansoya, R; Kalfa, T; Risinger, M; Low, PS. Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening. FASEB Journal. 2022; 36.

Forsyth, S; Schroeder, P; Geib, J; Vrishabhendra, L; Konstantinidis, DG; LaSalvia, K; Ribadeneira, MD; Wu, E; Kelly, P; Kalfa, TA. Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. Clinical Pharmacology in Drug Development. 2022; 11:654-665.

Schroeder, P; Fulzele, K; Forsyth, S; Ribadeneira, MD; Guichard, S; Wilker, E; Marshall, CG; Drake, A; Fessler, R; Konstantinidis, DG; et al. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. Journal of Pharmacology and Experimental Therapeutics. 2022; 380:210-219.

Tseng, SY; Gao, Z; Kalfa, TA; Ollberding, NJ; Tabbah, S; Keller, R; Cnota, JF. Altered erythropoiesis in newborns with congenital heart disease. Pediatric Research. 2022; 91:606-611.

Kalfa, TA. Diagnosis and clinical management of red cell membrane disorders. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2021; 2021:331-340.

Gutierrez, M; Shamoun, M; Seu, KG; Tanski, T; Kalfa, TA; Eniola-Adefeso, O. Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients. Scientific Reports. 2021; 11.

Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT. Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells, Molecules, and Diseases. 2021; 90.

Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; et al. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. British Journal of Haematology. 2021; 194:617-625.

Newby, GA; Yen, JS; Woodard, KJ; Mayuranathan, T; Lazzarotto, CR; Li, Y; Sheppard-Tillman, H; Porter, SN; Yao, Y; Mayberry, K; et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature. 2021; 595:295-302.

Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Pediatric Blood and Cancer. 2021; 68.

Sadaf, A; Seu, KG; Thaman, E; Fessler, R; Konstantinidis, DG; Bonar, HA; Korpik, J; Ware, RE; McGann, PT; Quinn, CT; et al. Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology. 2021; 12.

Brindley, EC; Papoin, J; Kennedy, L; Robledo, RF; Ciciotte, SL; Kalfa, TA; Peters, LL; Blanc, L. Rasa3 regulates stage-specific cell cycle progression in murine erythropoiesis. Blood Cells, Molecules, and Diseases. 2021; 87.

Niss, O; Lorsbach, RB; Berger, M; Chonat, S; McLemore, M; Buchbinder, D; McCavit, T; Shaffer, LG; Simpson, J; Schwartz, JH; et al. Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood Cells, Molecules, and Diseases. 2021; 87.

Kim, S; Khoriaty, R; Li, L; McClune, M; Kalfa, TA; Wu, J; Peltier, D; Fujiwara, H; Sun, Y; Oravecz-Wilson, K; et al. ER-to-Golgi transport and SEC23-dependent COPII vesicles regulate T cell alloimmunity. Journal of Clinical Investigation. 2021; 131.

Voulgaridou, A; Kalfa, TA. Autoimmune Hemolytic Anemia in the Pediatric Setting. Journal of Clinical Medicine. 2021; 10.

Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al. VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. American Journal of Human Genetics. 2020; 107:1149-1156.

Remiker, A; Haslam, D; Kalfa, TA. A painless erythematous swelling of the external ear as a manifestation of Lyme disease: a case report. Journal of Medical Case Reports. 2020; 14.

Rai, P; Roy, S; Konstantinidis, DG; Ponny, SR; Mpollo, ME M; Shrestha, A; Kalfa, TA; Malik, P. Angiotensin Signaling Is Essential for Stress Erythropoiesis but Results in Retention of Dysfunctional Mitochondria in Erythrocytes That Generate Excessive Reactive Oxygen Species. Blood. 2020; 136:31-32.

Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT. Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia. Blood. 2020; 136:16-17.

Brown, RC; Cruz, K; Kalfa, TA; Kuypers, FA; Saraf, SL; Estepp, JH; Smart, LR; Malik, P; Lerman, M; Mayer, R; et al. FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. Blood. 2020; 136:19-20.

Rothman, JA; Stevens, JL; Gray, FL; Kalfa, TA. How I approach hereditary hemolytic anemia and splenectomy. Pediatric Blood and Cancer. 2020; 67.

Risinger, M; Kalfa, TA. Red cell membrane disorders: structure meets function. Blood. 2020; 136:1250-1261.

Noomuna, P; Risinger, M; Zhou, S; Seu, K; Man, Y; An, R; Sheik, DA; Wan, J; Little, JA; Gurkan, UA; et al. Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease. British Journal of Haematology. 2020; 190:599-609.

Hall, BJ; Reiter, AJ; Englum, BR; Rice, HE; Rothman, JA; Davidoff, AM; Nottage, K; Oldham, KT; Scott, JP; Smithers, CJ; et al. Long‐term hematologic and clinical outcomes of splenectomy in children with hereditary spherocytosis and sickle cell disease. Pediatric Blood and Cancer. 2020; 67.

Niss, O; Lorsbach, RB; Buchbinder, DK; Chonat, S; McLemore, ML; McCavit, T; Schwartz, JH; Meznarich, J; Seu, K; Zhang, W; et al. Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR). Blood. 2019; 134:3521-3521.

McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. American Journal of Hematology. 2019; 94:871-879.

Chonat, S; Risinger, M; Sakthivel, H; Niss, O; Rothman, JA; Hsieh, L; Chou, ST; Kwiatkowski, JL; Khandros, E; Gorman, MF; et al. The Spectrum of SPTA1-Associated Hereditary Spherocytosis. Frontiers in Physiology. 2019; 10.

Risinger, M; Emberesh, M; Kalfa, TA. Rare Hereditary Hemolytic Anemias: Diagnostic Approach and Considerations in Management. Hematology/Oncology Clinics of North America. 2019; 33:373-392.

Risinger, M; Christakopoulos, GE; Schultz, CL; McGann, PT; Zhang, W; Kalfa, TA. Hereditary elliptocytosis-associated alpha-spectrin mutation p.L155dup as a modifier of sickle cell disease severity. Pediatric Blood and Cancer. 2019; 66.

Bianchi, P; Fermo, E; Glader, B; Kanno, H; Agarwal, A; Barcellini, W; Eber, S; Hoyer, JD; Kuter, DJ; Maia, TM; et al. Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. American Journal of Hematology. 2019; 94:149-161.

Kalfa, TA. Acquired Hemolytic Anemias. Concise Guide to Hematology. 2019.

Chonat, S; McLemore, ML; Bunting, ST; Nortman, S; Zhang, K; Kalfa, TA. Congenital dyserythropoietic anaemia type I diagnosed in a young adult with a history of splenectomy in childhood for presumed haemolytic anaemia. British Journal of Haematology. 2018; 182.

Konstantinidis, DG; Kalfa, TA. Rac GTPase. Encyclopedia of Signaling Molecules. 2018.

Risinger, M; Glogowska, E; Chonat, S; Zhang, K; Dagaonkar, N; Joiner, CH; Quinn, CT; Kalfa, TA; Gallagher, PG. Hereditary xerocytosis: Diagnostic considerations. American Journal of Hematology. 2018; 93:E67-E69.

Lesmana, H; Dyer, L; Li, X; Denton, J; Griffiths, J; Chonat, S; Seu, KG; Heeney, MM; Zhang, K; Hopkin, RJ; et al. Alu element insertion in PKLR gene as a novel cause of pyruvate kinase deficiency in Middle Eastern patients. Human Mutation. 2018; 39:389-393.

Wang, J; Hayashi, Y; Yokota, A; Xu, Z; Zhang, Y; Huang, R; Yan, X; Liu, H; Ma, L; Azam, M; et al. Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models. Haematologica. 2018; 103:40-50.

Kalfa, T; McGrath, KE. Analysis of Erythropoiesis Using Imaging Flow Cytometry. Methods in Molecular Biology. 2018; 1698:175-192.